Classifications: antineoplastic; aromatase inhibitor, steroidal; antiestrogen; Therapeutic: antineoplastic; steroidal aromatase inhibitor
Pregnancy Category: D
25 mg tablet
Steroidal aromatase inhibitor that suppresses plasma estrogens estradiol and estrone without affecting cortisol or aldosterone
synthesis in the adrenal glands. The enzyme, aromatase converts estrone to estradiol.
Breast tumor regression is possible in postmenopausal women. Effectiveness is indicated by evidence of tumor regression.
Estrogen-receptor positive early breast cancer following treatment with tamoxifen, treatment of advanced breast cancer in
postmenopausal women whose disease has progressed following tamoxifen therapy.
Hypersensitivity to exemestane; pregnancy (category D), lactation. Safety and efficay in children not established.
Hepatic or renal insufficiency; GI disorders; cardiovascular disease; hyperlipidemia.
Route & Dosage
|Early and Advanced Breast Cancer
Adult: PO 25 mg q.d. after a meal
- Give following a meal.
- Store at 15°30° C (59°86° F).
Adverse Effects (≥1%)Body as a Whole: Fatigue, hot flashes, pain,
; edema; fever; paresthesia
. CNS: Depression, insomnia, anxiety;
dizziness; headache. CV:
Hypertension. GI: Nausea,
vomiting, abdominal pain, anorexia, constipation
, increased appetite. Respiratory: Dyspnea
, cough, bronchitis
Increased sweating, rash, itching. Other:
Rapidly, approximately 42% reaches systemic circulation. Distribution:
distribution, 90% protein bound. Metabolism:
Extensively in liver (CYP3A4). Elimination:
Equally in urine and feces. Half-Life:
Assessment & Drug Effects
- Lab tests: Baseline liver function, BUN and creatinine; periodic WBC with differential, lipid profile, routine blood chemistry.
Patient & Family Education
- Review manufacturer's patient literature thoroughly to reinforce understanding of likely adverse effects.
- Report bothersome adverse effects to physician.